Focus box
ObvioHealth Q&A: connecting DCT dots with remote tech
The move towards decentralised clinical trials has been accelerated by Covid-19, and the tech that underpins remote trials is evolving…
AD/PD 2021: Biogen could enable efficient patient screening for both clinical trials and clinical practice in Alzheimer’s disease
During the Aβ targeting therapies symposium at this month's International Virtual Conference on Alzheimer’s Disease and Parkinson’s Disease (AD/PD 2021),…
J&J’s single-shot Covid-19 vaccine: the journey to approval
Last week, hot on the heels of an FDA emergency use authorisation (EUA), Johnson & Johnson (J&J) subsidiary Janssen’s Covid-19…
Q&A with N-SIDE’s Sébastien Coppe: how digitisation overcomes clinical bottlenecks
The World Health Organization declared the Covid-19 crisis to be a pandemic in mid-March 2020. Nine months later, three vaccines…
Inactivated SARS-CoV-2 vaccines unlikely candidates for undercutting spike-mutation variants of concern
Despite the theoretical potential of inactivated virus vaccines to offer a lead over other Covid-19 vaccine technologies against variants of…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
New SARS-CoV-2 variants push Covid-19 vaccine long-term durability questions to back seat
Long-term Covid-19 vaccine durability has become less of an endgame since it has become increasingly likely additional shots will be…
Trial resumptions slowing due to new Covid-19 strains
Since early March 2020, more than 500 companies have publicly announced disruptions to their planned and ongoing clinical trials due…
Johnson & Johnson’s single-shot Covid-19 vaccine best used to control outbreak, while Novavax’s vaccine shows better overall protection
With Johnson & Johnson (J&J) and Novavax, two more companies presented Covid-19 vaccine efficacy data last week. With an efficacy…
Covid-19 may result in brain damage and increase the risk of dementia
There are now more than 95 million confirmed cases of Covid-19 worldwide. The disease has reached 193 countries, with the…
Regeneron reports positive interim data from Covid-19 trial
Regeneron Pharmaceuticals has reported positive initial results from an ongoing Phase III clinical trial of antibody cocktail REGEN-COV used as…